Niagen Bioscience Inc
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Robert N. Fried
- Full Time Employees
- 117
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 10900 Wilshire Blvd, Suite 600 Los Angeles CA United States of America 90024
- IPO Date
- Jun 24, 2015
- CIK
- 0001386570
- Website
- niagenbioscience.com
- Similar Companies
- Business
- Niagen Bioscience Inc (Ticker: NAGE) develops and commercializes innovative bioscience products focused on cellular health and energy metabolism, primarily through nicotinamide riboside (NR) branded as Niagen, a clinically validated precursor to NAD+ that supports mitochondrial function and healthy aging. The company offers Niagen in various formulations, including bulk ingredients for dietary supplements, branded consumer products such as capsules and powders, and custom formulations for sports nutrition and longevity markets; it also provides research-grade Niagen for clinical studies and contract manufacturing services for NAD+-boosting nutraceuticals. Headquartered in Reno, Nevada, Niagen Bioscience was founded in 2013 as part of the ChromaDex ecosystem before spinning out as an independent entity, with operations spanning North America, Europe, and Asia-Pacific targeting supplement manufacturers, healthcare professionals, and direct-to-consumer channels in the nutraceutical and wellness industries. In late 2024, the company completed a significant uplisting to NASDAQ under ticker NAGE following a reverse merger, enhancing its capital access for global expansion; it announced a strategic partnership with a leading Asian distributor to accelerate Niagen adoption in the high-growth longevity market and launched Niagen Pro, a professional-grade line for practitioners in 2025. Niagen Bioscience continues to invest in R&D for next-generation NAD+ precursors amid rising demand for anti-aging interventions, with no major subsidiaries but key alliances with contract manufacturers worldwide.
Company News
Niagen Bioscience to Present at Longevity Investors Conference
Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit
Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit
Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam's Club
Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam's Club
Niagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor Conference
Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence
Niagen Bioscience, Inc. (NAGE) Q2 2026 Earnings Call Transcript
Niagen Bioscience (NAGE) Meets Q2 Earnings Estimates
Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results
Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168
Niagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen® (Patented Nicotinamide Riboside, NR) Supplementation Improved a Muscle-Specific Marker of Biologic
Niagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen® (Patented Nicotinamide Riboside, NR) Supplementation Improved a Muscle-Specific Marker of Biological Aging
Niagen Bioscience to Present at Canaccord Genuity's 46th Annual Growth Conference
Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
Niagen Bioscience Appoints Abhijit Kale, Ph.D., as Senior Director of Global External Research
Niagen Bioscience, Inc. (NAGE) Discusses Strategic Expansion Into Pharmaceutical Development and NB4168 Drug Program Transcript
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)
Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026